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ABSTRACT
This study outlines the unique epidemiology of Salmonella enterica serotype Virchow in Israel. Between
1997 and 2002, the overall incidence of non-typhoid Salmonella enterica (NTS) decreased from 69.3 to 53.3
infections ⁄ 100 000 population, but the incidence of S. Virchow increased (from 7.2 to 9.1 infec-
tions ⁄ 100 000). Since 2000, S. Virchow has become the second-ranking NTS isolate, accounting for 17%
and 27% of all stool and blood NTS isolates, respectively. Infants aged < 1 year had the highest
incidence of isolation from stools (92.8 ⁄ 100 000). The incidence of isolation from blood was highest for
infants aged <1 year (4.4 ⁄ 100 000). Only 6% of isolates were susceptible to all ten antibiotic agents
tested; 34%were resistant to one agent, 54% to one to three agents, and 40% to four to six agents. A high
proportion of the tested isolates were resistant to nalidixic acid (89%), streptomycin (56%), tetracycline
(43%), trimethoprim–sulphamethoxazole (38%) and chloramphenicol (28%), but none to ciproﬂoxacin
or ceftriaxone. Pulsed-ﬁeld gel electrophoresis revealed two closely related clusters, each containing a
predominant pulsotype. Coupled with its invasive propensity, the increasing incidence of highly
resistant S. Virchow in Israel is of real concern. Future research should focus on the sources of
S. Virchow in the food chain in order to institute effective control measures.
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INTRODUCTION
Non-typhoid Salmonella enterica (NTS) is the cause
of a worldwide pandemic of foodborne infections
and is a major threat to public health [1–4]. The
genus Salmonella is divided into six subspecies,
according to fermentative properties, and into
c. 2500 serotypes according to polymorphism in
the lipopolysaccharide (O antigen) and ﬂagellar
(H antigen) structures [5]. About 200 serotypes
are capable of infecting humans, but only a
few have assumed great signiﬁcance. In most
developed countries, S. enterica serotype Enterit-
idis and S. enterica serotype Typhimurium are
responsible for the vast majority of NTS infections
[6]. S. enterica serotype Virchow ranks third in
many European countries, but accounts for < 4%
of all NTS serotypes [2] (http://www.who.int/
salmsurv/en). In the Americas, S. Virchow is an
infrequent cause of human salmonellosis and
accounts for < 1% of all NTS isolates [7] (http://
www.who.int/salmsurv/en). The highest rates
(7.5%) are reported from Australia, where the
vast majority of cases originate from the northern
states, particularly north Queensland [8] (http://
www.who.int/salmsurv/en).
In Israel, only a few sporadic cases of S. Vir-
chow were recorded until 1988. Since then, the
prevalence of this serotype has increased rapidly,
Corresponding author and reprint requests: S. Yaron, Depart-
ment of Biotechnology and Food Engineering, Technion-Israel
Institute of Technology, Haifa 32000, Israel
E-mail: simay@techunix.technion.ac.il
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
and it has become a dominant cause of NTS
illness in Israel [9]. The present study outlines the
classical and molecular epidemiology of S. Vir-
chow in Israel during a 6-year period.
MATERIALS AND METHODS
Epidemiology
During 1997–2002, epidemiological data concerning NTS were
retrieved via two systems. The ﬁrst was a system of passive
submission to the Government Central Laboratories (Public
Health Services, Israel Ministry of Health, Jerusalem). As
salmonellosis is a reportable disease in Israel, human Salmon-
ella isolates from all sources are submitted passively by all
microbiology laboratories in the country to the Government
Central Laboratories, where demographic data are collected
and ﬁnal serological identiﬁcation is performed according to
the Kauffmann–White scheme [10]. The second system was an
active sentinel laboratory-based surveillance network for
enteric diseases that was established by the Israel Center for
Disease Control (ICDC) in June 1997. This network includes
eight sentinel (community and hospital) microbiological
laboratories located throughout the country. Demographic
data concerning Salmonella isolates were collected once or
twice monthly by the ICDC data centre. The corresponding
Salmonella isolates were submitted actively to the Government
Central Laboratories for ﬁnal serological identiﬁcation; the
results were collected by the ICDC data centre and added to
the demographic database. The data from the sentinel labor-
atory surveillance system are included in the database of the
Government Central Laboratories, and contributed c. 25% of
all NTS isolates during the study period. For every patient,
isolates of the same NTS serotype from the same source in the
same year were counted only once. Data concerning the
distribution of the Israeli population according to age
group were retrieved from the Israeli Central Bureau of
Statistics [11].
Bacterial isolates
After serological identiﬁcation, the Government Central Labor-
atories store a random sample from each of the various
Salmonella serotypes for further analyses on a yearly basis. In
total, 170 stored isolates of S. Virchow from stool and blood
samples submitted between 1997 and 2002 were available for
susceptibility testing. Of these, 159 were also analysed by
pulsed-ﬁeld gel electrophoresis (PFGE). Other NTS serotypes
(Enteritidis, Typhimurium, Hadar and Agona) isolated from
stool or blood samples during the same period were available
for comparative PFGE studies (see below). Bacteria were
stored in glycerol 20% v ⁄v at ) 70C.
Sensitivity tests
The Kirby–Bauer disk-diffusion method [12] was used to test
susceptibility to ten antimicrobial agents (disk content):
ampicillin (10 lg), ceftriaxone (30 lg), chloramphenicol
(30 lg), ciproﬂoxacin (5 lg), gentamicin (5 lg), nalidixic
acid (30 lg), neomycin (30 lg), streptomycin (10 lg), tetra-
cycline (30 lg) and trimethoprim–sulphamethoxazole 1:19
(25 lg).
Typing by PFGE
Salmonella isolates were analysed by PFGE as described
previously [13]. Chromosomal DNA was digested with XbaI
(New England Biolabs, Beverly, MA, USA) and the fragments
were separated using a CHEF-DR III PFGE apparatus (Bio-
Rad, Hercules, CA, USA). The pulse time was ramped from 2.2
to 63.8 s for 18 h at 6 V ⁄ cm. After visual evaluation of digitised
images, the bands were analysed using Molecular Analyst
Fingerprinting Plus software v.1.6 (Bio-Rad). Pattern clustering
was performed using UPGMA (unweighted pair-group
method with averages) and the Dice coefﬁcient.
Statistical methods
Proportions were compared using the chi-square test and
two-tailed p values were calculated. Annual trends were
examined by performing Poisson regression, and incidence
rate ratios (IRRs) and 95% CIs were calculated. An IRR >1
indicates an increasing trend, while an IRR <1 indicates a
decrease in incidence by year. Analyses were performed
using STATA 8 software (Stata Corp., College Station, TX,
USA).
RESULTS
Data from passive submission to Government
Central Laboratories
During the study period (1 January 1997 to 31
December 2002), 23 582 stool isolates and 649
blood isolates were submitted passively to the
Government Central Laboratories, and these were
the major source of data for the present study
(Table 1). The age of the patient was known for
84.2% of the isolates submitted. S. Virchow
accounted for 3504 (15%) of all stool and 142
(22%) of all blood isolates. Other sources of
S. Virchow isolates were urine (22 isolates), pus
(three isolates) and cerebrospinal ﬂuid (one iso-
late). Of the S. Virchow isolates from stool
samples, 64% (2244 isolates) were submitted from
microbiology laboratories in the ambulatory set-
ting, and 36% (1257 isolates) from microbiology
laboratories within hospitals. The corresponding
percentages for blood isolates were 3% (ﬁve
isolates) and 97% (138 isolates). During the study
period the annual incidence of all Salmonella
serotypes isolated from stool samples decreased
from 69.3 ⁄ 100 000 population in 1997 to
53.3 ⁄ 100 000 in 2002 (IRR 0.94, 95% CI 0.89–0.99;
p 0.048). At the same time, the annual incidence
of stool isolates of S. Virchow increased from
7.7 ⁄ 100 000 population in 1997 to 9.1 ⁄ 100 000 in
2002. The highest incidence was observed in the
year 2000, with a peak of 13.1 ⁄ 100 000 population.
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The average incidence varied substantially
among age groups. The highest incidence of sub-
mitted stool isolates was observed for infants aged
< 1 year (92.8 ⁄ 100 000), followed by children aged
1–5 years (40.4 ⁄ 100 000). The incidence among
infants aged < 1 year was 30–40-fold higher than
among older children (aged 10–15 years) or adults,
and 17-fold higher than among those aged
> 65 years (5.1 ⁄ 100 000). The age-related incidence
of submitted blood isolates showed a similar
pattern: the highest incidencewas observed among
infants aged < 1 year (4.4 ⁄ 100 000), and the inci-
dencewas very low among older children or adults
(0–0.05 ⁄ 100 000). A slight increase in incidence
was observed among those aged > 65 years
(0.4 ⁄ 100 000). Invasiveness, calculated as the ratio
of blood isolates and blood plus stool isolates, was
high at the extremes of age (4.4 for infants aged
< 1 year, and 7 for those aged > 65 years), and low
in the age range 10–65 years (0–1.6).
The relative frequency of S. Virchow among
other NTS isolates increased gradually during the
study years (Table 1), and S. Virchow has ranked
second after S. Enteritidis since 2000. This trend
was even more prominent and statistically signi-
ﬁcant for blood isolates (IRR 1.13, 95% CI 1.03–
1.25; p 0.014). In the second half of the study
period (2000–2002), S. Virchow almost equalled
S. Enteritis in frequency and accounted for 27–
29% of all blood isolates.
Data from the active sentinel laboratory-based
surveillance network
Active retrieval of data from the network of
sentinel laboratories between 1 June 1997 and 31
December 2002 yielded 5315 NTS stool isolates,
including 823 (15.5%) isolates of S. Virchow. Of
these, 53% (424 isolates) originated from micro-
biology laboratories in the ambulatory setting,
and 47% (374 isolates) from microbiology labor-
atories within four large hospitals. The annual
distribution of NTS serotypes was similar to that
reported to the Government Central Laboratories,
and the relative frequencies of S. Virchow for the
years 1998–2002 were 13% (141 isolates), 11%
(126), 19% (183), 16% (188) and 16% (159),
respectively.
Sensitivity tests
A high prevalence of resistance to one or more
antimicrobial agents was detected among the 170
S. Virchow isolates studied (Table 2). Only 6% of
the isolates were susceptible to all ten antimicro-
bial agents tested, with 24% showing resistance to
one antibiotic, 54% to one to three antibiotics, and
40% to four to six antibiotics. During the
study, the proportion of pan-susceptible strains
decreased from 27% in 1997 to 0% in 2002
(IRR 0.52, 95% CI 0.41–0.66; p < 0.001). At the
Table 1. Distribution of the ten serotypes of non-typhoid Salmonella enterica submitted most frequently to the Central
Government Laboratories, Israel during 1997–2002
Serotype 1997 n (%) 1998 n (%) 1999 n (%) 2000 n (%) 2001 n (%) 2002 n (%) Total n (%)
Stool isolates
Enteritidis 851 (21) 927 (22) 1354 (30) 862 (22) 929 (26) 1003 (29) 5926 (25)
Typhimurium 1061 (26) 888 (22) 543 (12) 531 (14) 576 (16) 490 (14) 4089 (17)
Virchow 449 (11) 528 (13) 518 (12) 823 (21) 587 (17) 599 (17) 3504 (15)
Hadar 561 (14) 677 (16) 671 (15) 438 (11) 285 (8) 188 (5) 2820 (12)
Infantis 223 (6) 294 (7) 411 (9) 120 (3) 69 (2) 75 (2) 1192 (5)
Bredeney 62 (2) 69 (2) 168 (4) 161 (4) 152 (4) 98 (3) 710 (3)
Agona 82 (2) 54 (1) 87 (2) 117 (3) 64 (2) 85 (2) 489 (2)
Heidelberg 21 (1) 17 (0.4) 6 (0.1) 6 (0.2) 130 (4) 272 (8) 452 (2)
Blockley 129 (3) 104 (3) 88 (2) 54 (1) 58 (2) 15 (0.4) 448 (2)
9,12:l,v 69 (2) 54 (1) 56 (1) 39 (1) 59 (2) 49 (1) 326 (1)
Other 532 (13) 513 (12) 539 (12) 773 (20) 641 (18) 628 (18) 3626 (15)
Total 4040 (100) 4125 (100) 4441 (100) 3924 (100) 3550 (100) 3502 (100) 23 582 (100)
Blood isolates
Enteritidis 48 (39) 36 (36) 52 (35) 28 (29) 30 (33) 26 (29) 220 (34)
Typhimurium 27 (22) 20 (20) 24 (16) 8 (8) 17 (19) 16 (18) 112 (17)
Virchow 21 (17) 17 (17) 26 (17) 28 (29) 26 (29) 24 (27) 142 (22)
Hadar 6 (5) 6 (6) 11 (7) 6 (6) 2 (2) 2 (2) 33 (5)
Infantis 4 (3) 5 (5) 12 (8) 3 (3) 1 (1) 1 (1) 26 (4)
Bredeney 1 (1) 4 (4) 8 (5) 12 (13) 6 (7) 3 (3) 34 (5)
Agona 0 1 (1) 0 0 0 1 (1) 2 (0.3)
Heidelberg 0 0 0 0 2 (2) 11 (12) 13 (2)
Blockley 1 (1) 1 (1) 0 0 0 0 2 (0.3)
9,12:l,v 3 (2) 4 (4) 3 (2) 3 (3) 0 1 (1) 14 (2)
Other 12 (10) 7 (7) 13 (9) 8 (8) 7 (8) 4 (4) 51 (8)
Total 123 (100) 101 (100) 149 (100) 96 (100) 91 (100) 89 (100) 649 (100)
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same time, resistance to two or more antimicro-
bial agents increased from 40% in 1997 to 83% in
2002 (IRR 1.12, 95% CI 1.05–1.19; p < 0.001).
The highest rate of resistance (89%) was to
nalidixic acid (Table 2). During the study, there
was a noticeable rise in resistance to tetracycline
(from 8% to 18%; IRR 1.07, 95% CI 1.00–1.15;
p 0.025) and to streptomycin (from 2% to 22%,
annual trend not signiﬁcant). The most common
multidrug resistance patterns were to trimetho-
prim–sulphamethoxazole (Sx), tetracycline (Te),
streptomycin (St), chloramphenicol (Ch) and
nalidixic acid (Na), i.e., SxTeStChNa (23%) and
SxTeStNa (8%). Only one (0.6%) isolate was
resistant to gentamicin, and none to ciproﬂoxacin
or ceftriaxone (Table 2).
PFGE analysis
PFGE analysis of 159 isolates showed 14 different
XbaI PFGE patterns or pulsotypes, grouped into
two major clusters, termed A and B. Most isolates
belonged to two predominant patterns, termed
A1 (86 isolates, 54%) and B1 (39 isolates, 24%),
which differed by only two bands. A 97-kb
fragment was observed in A1, and a 145-kb
fragment in B1. Using XhoI, a 270-kb fragment
was observed in A1, and a 220-kb fragment in B1.
Cluster A also included patterns A2 (ﬁve isolates),
A3 (ﬁve isolates), and A4, A5, A6, A7 and A8 (one
isolate each). Cluster B also included patterns B2
(12 isolates), B3 (four isolates), and B4, B6 and B7
(one isolate each). The pulsotypes in each cluster
differed by one to three bands. This was mostly
the result of deletion ⁄ insertion of DNA. Only
three pulsotypes (A4, A5 and B4) were the result
of gain ⁄ loss of the same restriction site. The
relative frequencies of the main PFGE pulsotypes
remained unchanged during the study period.
DISCUSSION
This study revealed a gradual increase in the
incidence of S. Virchow in Israel during the years
1997–2002, in contrast to a signiﬁcant decrease in
the overall incidence of NTS infections. Since the
year 2000, S. Virchow has become the second-
ranking NTS serotype, while S. Enteritidis has
remained the leading serotype. The decrease in
S. Typhimurium during the study period may
have contributed to this trend. In 2002, the ﬁnal
year of the study, S. Virchow accounted for 17%
of stool NTS isolates and 27% of blood NTS
isolates. This pattern is very different from the
recent epidemiology of NTS reported in most
countries [2,7] (http://www.who.int/salmsurv/
en). Currently, the highest national rates of
S. Virchow worldwide are reported from Israel.
S. Virchow was ﬁrst isolated in 1930 by Kauf-
mann from a patient with a typhoid-like illness
[14]. This serotype has been associated mostly
with sporadic infections and has been a cause of
occasional point source outbreaks in the UK [15],
but emerged during the 1980s as an important
cause of human salmonellosis. In Scotland, it
accounted for nearly 25% of conﬁrmed cases of
human salmonellosis [16], and in England and
Wales it ranked third among human Salmonella
serotypes, accounting for 6% of all isolates [17].
However, its incidence has since declined dra-
matically, and currently S. Virchow accounts for
< 2% of NTS isolates in the UK [7]. In Australia,
and particularly Queensland, S. Virchow has
been endemic since the mid-1980s [18].
The sources of S. Virchow in Israel have not
been identiﬁed. In the UK and Australia, poultry
have been implicated as the predominant source
[15,19–21]. Interestingly, the emergence of S. Vir-
chow among Israeli poultry has shown a remark-
able similarity to the trends among humans [9]
(E. Berman, personal communication). S. Virchow
appeared in poultry during the mid-1980s,
showed a sharp increase in prevalence during
the early 1990s, and has shown a gradual increase
since then, so that it now accounts for c. 25% of all
Table 2. Resistance patterns of 170 tested isolates of
Salmonella Virchow, Israel 1997–2002
Resistant isolates
n (%)
Antibiotics tested
Nalidixic acid 151 (89)
Streptomycin 96 (56)
Tetracycline 73 (43)
Trimethoprim–sulphamethoxazole 65 (38)
Chloramphenicol 48 (28)
Ampicillin 21 (12)
Neomycin 2 (1)
Gentamicin 1 (1)
Ciproﬂoxacin 0
Ceftriaxone 0
Number of antibiotic classes
to which the isolates were resistant
Zero 10 (6)
One 57 (34)
Two 27 (16)
Three 8 (5)
Four 20 (12)
Five 42 (25)
Six 6 (4)
1002 Clinical Microbiology and Infection, Volume 12 Number 10, October 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 999–1005
NTS serotypes isolated from poultry. In humans,
S. Virchow appeared in the late-1980s and has
now reached a similar frequency to that in poultry
among NTS serotypes causing human disease.
The possibility that poultry constitute the main
food source of S. Virchow in Israel should be
investigated by further research. Other food
sources of S. Virchow have been identiﬁed
worldwide, including infant milk formula
in Spain [22,23], garlic and dried tomatoes in
Australia [8], and hamburgers, ﬁsh, beef and veal
in the USA [24].
The burden of S. Virchow infection in the
present study was highest for infants aged
< 1 year, followed by children aged up to 5 years.
The blood invasiveness ratio was high at the two
extremes of age. S. Virchow is the predominant
cause of NTS bacteraemia in children aged
< 2 years in Israel, and is the most invasive
serotype in this age group [25] (International
Conference on Emerging Infectious Diseases,
Atlanta, abstract 82). In the present study, the
overall invasiveness ratio for S. Virchow was 3.9
(3.9 blood isolates for every 100 stool plus blood
isolates). Similar rates (3.8) were reported in
England and Wales during the 1980s [26]. The
invasive potential of S. Virchow is probably more
pronounced during outbreaks in various parts of
the world. For example, during a small outbreak
in Manchester, UK, in 1972 [15], 29% of isolates
were bacteraemic and one (5%) individual died.
In 1994, a nationwide outbreak of S. Virchow was
reported in Spain and was traced to contaminated
powdered infant milk formula. At least 48 infants
aged < 1 year were affected, of whom 31% had
bacteraemia and 6% had meningitis [27,28]. In a
recent outbreak in Victoria, Australia, associated
with fresh garlic and dried tomatoes, the bacter-
aemia rate was 13% and the mortality rate was
3% [8].
In addition to bacteraemia, S. Virchow is
capable of causing a range of extra-intestinal
infections, which may be associated with serious
morbidity and even mortality. Meningitis was
reported in six infants (aged 6 weeks to 6 months)
from northern Queensland, Australia [29,30].
Although none died, two infants had permanent
sequelae, with severe spastic quadriplegia and
developmental delay in one, and profound hear-
ing loss in the other [30]. S. Virchow has also been
associated with pyogenic infections in a variety of
body sites, including muscle, bone, joints, kidneys
and testicles, as well as intra-abdominal and sub-
phrenic sites [31–35].
A high degree of clonality was found among
the Israeli S. Virchow isolates during the present
study period. Analysis by PFGE revealed two
main clusters, which differed by one to three
bands. Similarly, investigation of a countrywide
outbreak of S. Virchow associated with infant
milk formula in Spain [22] revealed that the
suspected outbreak strains were divided into two
closely related PFGE subgroups, differing by
three bands. The outbreak strains showed a
pattern that was different from that of the strains
isolated in the years before the outbreak [22].
More recently, analysis of an outbreak in New
South Wales, Australia revealed that all human
and environmental S. Virchow isolates implicated
in the outbreak belonged to a single PFGE group
with 95% similarity [8]. Non-outbreak S. Virchow
isolates had a different pattern.
Of major concern in the present study were
the high rates of resistance to multiple antibiot-
ics, including 89% resistance to nalidixic acid,
56% to streptomycin, 43% to tetracycline, 38%
to trimethoprim–sulphamethoxazole, 29% to chl-
oramphenicol and 12% to ampicillin. In a recent
European survey [36], the corresponding rates
were 53%, 7%, 20%, 3% and 8%, respectively.
The proportion of fully-sensitive strains was
much lower in Israel than in European countries
(6% vs. 28%), although the proportions of
isolates resistant to four or more drugs were
similar (41% vs. 36%, respectively). Notably,
resistance to third-generation cephalosporins and
ciproﬂoxacin was not found in the present study.
The resistance patterns found among the Israeli
S. Virchow isolates resemble those found among
S. Virchow isolates in England and Wales
[37,38].
The main limitation of the present study is that
it was based largely on passive submission of
Salmonella isolates to the Government Central
Laboratories, which may result in an underesti-
mate of the true annual isolation rate. However,
there is no reason to assume preferential report-
ing of speciﬁc serotypes, so comparisons between
serotypes should be accurate. The similar sero-
type distribution results obtained actively via the
sentinel laboratory-based surveillance network
provide a validation of the national, laboratory-
based, passive surveillance system that has prom-
ising implications for future studies of enteric
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pathogens in Israel. A second potential bias
concerns missing information regarding the age
of patients. This may result in lower age-speciﬁc
isolation rates, but should not affect comparisons
among the various age groups.
The increasing incidence of multiple antibiotic-
resistant S. Virchow isolates in Israel is of real
concern, and should be the focus of more inten-
sive surveillance and intervention measures.
Research efforts, including case-control studies,
should concentrate on how S. Virchow enters the
food chain in Israel and the mechanisms of
antibiotic resistance and invasiveness.
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